Signaling effectors underlying pathologic growth and remodeling of the heart

Journal of Clinical Investigation

Volumn 123, Issue 1, 2013, Pages 37-45

  Van Berlo, Jop H ^a   Maillet, Marjorie ^a   Molkentin, Jeffery D ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; APICIDIN; BETA ADRENERGIC RECEPTOR; BETA ARRESTIN; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE KINASE; CALCIUM ION; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE 2; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PHOSPHODIESTERASE V; PROTEIN KINASE C ALPHA; RUBOXISTAURIN; SILDENAFIL; TADALAFIL; VARDENAFIL;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; BETA ADRENERGIC STIMULATION; CALCIUM CELL LEVEL; CALCIUM SIGNALING; DRUG EFFICACY; ENZYME INHIBITION; GENE OVEREXPRESSION; HEART DISEASE; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART REMODELING; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PULMONARY HYPERTENSION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ARRHYTHMIAS, CARDIAC; CARDIOMEGALY; CLINICAL TRIALS AS TOPIC; DEATH, SUDDEN; DISEASE MODELS, ANIMAL; HEART FAILURE; HUMANS; SIGNAL TRANSDUCTION; VENTRICULAR REMODELING;

EID: 84873868258     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI62839     Document Type: Review

References (159)

1. Karsner HT, Saphir O, Todd TW. The state of the cardiac muscle in hypertrophy and atrophy. Am J Pathol. 1925;1(4): 351-372.
2. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990; 322(22): 1561-1566.
3. Levy D, Anderson KM, Savage DD, Balkus SA, Kannel WB, Castelli WP. Risk of ventricular arrhythmias in left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol. 1987;60(7): 560-565.
4. Drazner MH, et al. Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study. J Am Coll Cardiol. 2004;43(12): 2207-2215.
5. de Simone G, Gottdiener JS, Chinali M, Maurer MS. Left ventricular mass predicts heart failure not related to previous myocardial infarction: the Cardiovascular Health Study. Eur Heart J. 2008; 29(6): 741-747.
6. Grossman W, Jones D, McLaurin LP. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest. 1975;56(1): 56-64.
7. Lee WC, Shideman FE. Role of myocardial catecholamines in cardiac contractility. Science. 1959; 129(3354): 967-968.
8. Taylor RR, Covell JW, Ross J Jr. Left ventricular function in experimental aorto-caval fistula with circulatory congestion and fluid retention. J Clin Invest. 1968;47(6): 1333-1342.
9. Hood WP Jr, Rackley CE, Rolett EL. Wall stress in the normal and hypertrophied human left ventricle. Am J Cardiol. 1968;22(4): 550-558.
10. Sharif-Naeini R, et al. Sensing pressure in the cardiovascular system: Gq-coupled mechanoreceptors and TRP channels. J Mol Cell Cardiol. 2010;48(1): 83-89.
11. Weeks KL, McMullen Jr. The athlete's heart vs. The failing heart: can signaling explain the two distinct outcomes? Physiology (Bethesda). 2011;26(2): 97-105.
12. Perrino C, et al. Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction. J Clin Invest. 2006; 116(6): 1547-1560.
13. Tanaka N, et al. Effects of growth hormone and IGF-I on cardiac hypertrophy and gene expression in mice. Am J Physiol. 1998;275(2 pt 2):H393-H399.
14. McMullen JR, et al. The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase(p110alpha) pathway. J Biol Chem. 2004;279(6): 4782-4793.
15. Shiojima I, et al. Akt signaling mediates postnatal heart growth in response to insulin and nutritional status. J Biol Chem. 2002;277(40): 37670-37677.
16. Pallafacchina G, Calabria E, Serrano AL, Kalhovde JM, Schiaffino S. A protein kinase B-dependent and rapamycin-sensitive pathway controls skeletal muscle growth but not fiber type specification. Proc Natl Acad Sci U S A. 2002;99(14): 9213-9218.
17. Rommel C, et al. Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science. 1999;286(5445): 1738-1741.
18. Bostrom P, et al. C/EBPbeta controls exercise-induced cardiac growth and protects against pathological cardiac remodeling. Cell. 2010;143(7): 1072-1083.
19. Sussman MA, et al. Myocardial AKT: the omnipresent nexus. Physiol Rev. 2011;91(3): 1023-1070.
20. Whitworth JA. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21(11): 1983-1992.
21. Chobanian AV, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289(19): 2560-2572.
22. Feron O, Salomone S, Godfraind T. Action of the calcium channel blocker lacidipine on cardiac hypertrophy and endothelin-1 gene expression in stroke-prone hypertensive rats. Br J Pharmacol. 1996; 118(3): 659-664.
23. Sekiguchi K, et al. Cross-regulation between the renin-angiotensin system and inflammatory mediators in cardiac hypertrophy and failure. Cardiovasc Res. 2004;63(3): 433-442.
24. Feldman DS, Carnes CA, Abraham WT, Bristow MR. Mechanisms of disease: beta-adrenergic receptors - alterations in signal transduction and pharmacogenomics in heart failure. Nat Clin Pract Cardiovasc Med. 2005;2(9): 475-483.
25. Calhoun DA, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Pro fessional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008; 51(6): 1403-1419.
26. Roger VL, et al. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation. 2012;125(1):e2-e220.
27. Packer M, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334(21): 1349-1355.
28. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366(9496): 1545-1553.
29. Snow PJ. Effect of propranolol in myocardial infarction. Lancet. 1965;2(7412): 551-553.
30. Freemantle N, Cleland J, Young P, Mason J, Harrison J. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318(7200): 1730-1737.
31. Remme WJ. Pharmacological modulation of cardiovascular remodeling: a guide to heart failure therapy. Cardiovasc Drugs Ther. 2003;17(4): 349-360.
32. Lohse MJ, Engelhardt S, Eschenhagen T. What is the role of beta-adrenergic signaling in heart failure? Circ Res. 2003;93(10): 896-906.
33. Rockman HA, Choi DJ, Rahman NU, Akhter SA, Lefkowitz RJ, Koch WJ. Receptor-specific in vivo desensitization by the G protein-coupled receptor kinase-5 in transgenic mice. Proc Natl Acad Sci U S A. 1996;93(18): 9954-9959.
34. Rockman HA, Koch WJ, Milano CA, Lefkowitz RJ. Myocardial beta-adrenergic receptor signaling in vivo: insights from transgenic mice. J Mol Med (Berl). 1996;74(9): 489-495.
35. Strulovici B, Cerione RA, Kilpatrick BF, Caron MG, Lefkowitz RJ. Direct demonstration of impaired functionality of a purified desensitized beta-adrenergic receptor in a reconstituted system. Science. 1984;225(4664): 837-840.
36. Benovic JL, Strasser RH, Caron MG, Lefkowitz RJ. Beta-adrenergic receptor kinase: identification of a novel protein kinase that phosphorylates the agonist- occupied form of the receptor. Proc Natl Acad Sci U S A. 1986;83(9): 2797-2801.
37. Rockman HA, et al. Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc Natl Acad Sci U S A. 1998;95(12): 7000-7005.
38. Raake PW, et al. G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure. Circ Res. 2008;103(4): 413-422.
39. Shah AS, et al. In vivo ventricular gene delivery of a beta-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction. Circulation. 2001;103(9): 1311-1316.
40. Casey LM, et al. Small molecule disruption of G beta gamma signaling inhibits the progression of heart failure. Circ Res. 2010;107(4): 532-539.
41. Rajagopal S, Rajagopal K, Lefkowitz RJ. Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat Rev Drug Discov. 2010;9(5): 373-386.
42. Rajagopal K, et al. Beta-arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes. Proc Natl Acad Sci U S A. 2006;103(44): 16284-16289.
43. Wei H, et al. Independent beta-arrestin 2 and G protein- mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci U S A. 2003;100(19): 10782-10787.
44. Whalen EJ, Rajagopal S, Lefkowitz RJ. Therapeutic potential of beta-arrestin- and G protein-biased agonists. Trends Mol Med. 2011;17(3): 126-139.
45. Poole-Wilson PA, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362(9377): 7-13.
46. Dorn GW 2nd, Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest. 2005;115(3): 527-537.
47. Braz JC, et al. PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat Med. 2004;10(3): 248-254.
48. Hambleton M, et al. Inducible and myocyte-specific inhibition of PKCalpha enhances cardiac contractility and protects against infarction-induced heart failure. Am J Physiol Heart Circ Physiol. 2007; 293(6):H3768-H3771.
49. Hambleton M, et al. Pharmacological- and gene therapy-based inhibition of protein kinase Calpha/beta enhances cardiac contractility and attenuates heart failure. Circulation. 2006;114(6): 574-582.
50. Wang GS, Kuyumcu-Martinez MN, Sarma S, Mathur N, Wehrens XH, Cooper TA. PKC inhibition ameliorates the cardiac phenotype in a mouse model of myotonic dystrophy type 1. J Clin Invest. 2009;119(12): 3797-3806.
51. Boyle AJ, et al. Inhibition of protein kinase C reduces left ventricular fibrosis and dysfunction following myocardial infarction. J Mol Cell Cardiol. 2005; 39(2): 213-221.
52. Connelly KA, et al. Inhibition of protein kinase C-beta by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy. Circ Heart Fail. 2009; 2(2): 129-137.
53. Kong L, et al. PKCbeta modulates ischemia-reperfusion injury in the heart. Am J Physiol Heart Circ Physiol. 2008;294(4):H1862-H1870.
54. Ladage D, et al. Inhibition of PKCalpha/beta with ruboxistaurin antagonizes heart failure in pigs after myocardial infarction injury. Circ Res. 2011; 109(12): 1396-1400.
55. Liu Q, et al. Protein kinase C{alpha}, but not PKC{beta} or PKC{gamma}, regulates contractility and heart failure susceptibility: implications for ruboxistaurin as a novel therapeutic approach. Circ Res. 2009;105(2): 194-200.
56. Belin RJ, et al. Augmented protein kinase C-alphainduced myofilament protein phosphorylation contributes to myofilament dysfunction in experimental congestive heart failure. Circ Res. 2007; 101(2): 195-204.
57. Hidalgo C, et al. PKC phosphorylation of titin's PEVK element: a novel and conserved pathway for modulating myocardial stiffness. Circ Res. 2009; 105(7): 631-638.
58. Kooij V, et al. Protein kinase C alpha and epsilon phosphorylation of troponin and myosin binding protein C reduce Ca2+ sensitivity in human myocardium. Basic Res Cardiol. 2010;105(2): 289-300.
59. Sumandea MP, Pyle WG, Kobayashi T, de Tombe PP, Solaro RJ. Identification of a functionally critical protein kinase C phosphorylation residue of cardiac troponin T. J Biol Chem. 2003;278(37): 35135-35144.
60. Cleland JG, et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebocontrolled, crossover, dose-ranging phase 2 trial. Lancet. 2011;378(9792): 676-683.
61. Malik FI, et al. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science. 2011;331(6023): 1439-1443.
62. Teerlink JR, et al. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-inman study. Lancet. 2011;378(9792): 667-675.
63. Davis MD, et al. Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema. Invest Ophthalmol Vis Sci. 2009;50(1): 1-4.
64. Aiello LP, et al. Oral protein kinase c beta inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C beta Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C beta Inhibitor-Diabetic Retinopathy Study 2. Retina. 2011;31(10): 2084-2094.
65. Sheetz MJ, Aiello LP, Shahri N, Davis MD, Kles KA, Danis RP. Effect of ruboxistaurin (RBX) On visual acuity decline over a 6-year period with cessation and reinstitution of therapy: results of an openlabel extension of the Protein Kinase C Diabetic Retinopathy Study 2 (PKC-DRS2). Retina. 2011; 31(6): 1053-1059.
66. Liu Q, Molkentin JD. Protein kinase Calpha as a heart failure therapeutic target. J Mol Cell Cardiol. 2011;51(4): 474-478.
67. Anderson ME, Brown JH, Bers DM. CaMKII in myocardial hypertrophy and heart failure. J Mol Cell Cardiol. 2011;51(4): 468-473.
68. Erickson JR, He BJ, Grumbach IM, Anderson ME. CaMKII in the cardiovascular system: sensing redox states. Physiol Rev. 2011;91(3): 889-915.
69. Zhang R, et al. Calmodulin kinase II inhibition protects against structural heart disease. Nat Med. 2005;11(4): 409-417.
70. De Koninck P, Schulman H. Sensitivity of CaM kinase II to the frequency of Ca2+ oscillations. Science. 1998;279(5348): 227-230.
71. Erickson JR, et al. A dynamic pathway for calciumindependent activation of CaMKII by methionine oxidation. Cell. 2008;133(3): 462-474.
72. Zhang T, et al. The cardiac-specific nuclear delta(B) isoform of Ca2+/calmodulin-dependent protein kinase II induces hypertrophy and dilated cardiomyopathy associated with increased protein phosphatase 2A activity. J Biol Chem. 2002; 277(2): 1261-1267.
73. Zhang T, et al. The deltaC isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure. Circ Res. 2003; 92(8): 912-919.
74. Backs J, et al. The delta isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload. Proc Natl Acad Sci U S A. 2009;106(7): 2342-2347.
75. Ling H, et al. Requirement for Ca2+/calmodulindependent kinase II in the transition from pressure overload-induced cardiac hypertrophy to heart failure in mice. J Clin Invest. 2009;119(5): 1230-1240.
76. Tsuji Y, et al. Ca(2+)-related signaling and protein phosphorylation abnormalities play central roles in a new experimental model of electrical storm. Circulation. 2011;123(20): 2192-2203.
77. van Oort RJ, et al. Ryanodine receptor phosphorylation by calcium/calmodulin-dependent protein kinase II promotes life-threatening ventricular arrhythmias in mice with heart failure. Circulation. 2010;122(25): 2669-2679.
78. He BJ, et al. Oxidation of CaMKII determines the cardiotoxic effects of aldosterone. Nat Med. 2011; 17(12): 1610-1618.
79. Westra J, et al. Role for CaMKII inhibition in rheumatoid arthritis: effects on HIF-1-induced VEGF production by rheumatoid synovial fibroblasts. Ann N Y Acad Sci. 2009;1173: 706-711.
80. Vandeput F, et al. cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium. J Pharmacol Exp Ther. 2009;330(3): 884-891.
81. Takimoto E, et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med. 2005;11(2): 214-222.
82. Chau VQ, Salloum FN, Hoke NN, Abbate A, Kukreja RC. Mitigation of the progression of heart failure with sildenafil involves inhibition of RhoA/Rho-kinase pathway. Am J Physiol Heart Circ Physiol. 2011;300(6):H2272- H2279.
83. Nagayama T, et al. Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre existing advanced hypertrophy caused by pressure overload. J Am Coll Cardiol. 2009;53(2): 207-215.
84. Schwartz BG, Levine LA, Comstock G, Stecher VJ, Kloner RA. Cardiac uses of phosphodiesterase-5 inhibitors. J Am Coll Cardiol. 2012;59(1): 9-15.
85. Giannetta E, et al. Chronic Inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging. Circulation. 2012;125(19): 2323-2333.
86. Movsesian M, Stehlik J, Vandeput F, Bristow MR. Phosphodiesterase inhibition in heart failure. Heart Fail Rev. 2009;14(4): 255-263.
87. Nagendran J, et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation. 2007; 116(3): 238-248.
88. Dorn GW 2nd, Molkentin JD. Manipulating cardiac contractility in heart failure: data from mice and men. Circulation. 2004;109(2): 150-158.
89. Koitabashi N, et al. Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation novel mechanism of cardiac stress modulation by PDE5 inhibition. J Mol Cell Cardiol. 2010; 48(4): 713-724.
90. Nishida M, et al. Phosphorylation of TRPC6 channels at Thr69 is required for anti-hypertrophic effects of phosphodiesterase 5 inhibition. J Biol Chem. 2010;285(17): 13244-13253.
91. Takimoto E, et al. Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. J Clin Invest. 2009;119(2): 408-420.
92. Fukui S, et al. Long-term inhibition of Rho-kinase ameliorates diastolic heart failure in hypertensive rats. J Cardiovasc Pharmacol. 2008;51(3): 317-326.
93. Shi J, Zhang L, Wei L. Rho-kinase in development and heart failure: insights from genetic models. Pediatr Cardiol. 2011;32(3): 297-304.
94. Raman M, Chen W, Cobb MH. Differential regulation and properties of MAPKs. Oncogene. 2007; 26(22): 3100-3112.
95. Rose BA, Force T, Wang Y. Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. Physiol Rev. 2010; 90(4): 1507-1546.
96. Gutkind JS, Offermanns S. A new G(q)-initiated MAPK signaling pathway in the heart. Dev Cell. 2009;16(2): 163-164.
97. Haq S, et al. Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation. 2001; 103(5): 670-677.
98. Toischer K, et al. Differential cardiac remodeling in preload versus afterload. Circulation. 2010; 122(10): 993-1003.
99. Bueno OF, et al. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J. 2000;19(23): 6341-6350.
100. Lips DJ, et al. MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo. Circulation. 2004;109(16): 1938-1941.
101. Bueno OF, et al. The dual-specificity phosphatase MKP-1 limits the cardiac hypertrophic response in vitro and in vivo. Circ Res. 2001;88(1): 88-96.
102. Purcell NH, et al. Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo. Proc Natl Acad Sci U S A. 2007;104(35): 14074-14079.
103. Kehat I, et al. Extracellular signal-regulated kinases 1 and 2 regulate the balance between eccentric and concentric cardiac growth. Circ Res. 2011;108(2): 176-183.
104. Haura EB, et al. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res. 2010;16(8): 2450-2457.
105. Liao P, et al. The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy. Proc Natl Acad Sci U S A. 2001;98(21): 12283-12288.
106. Wang Y, Su B, Sah VP, Brown JH, Han J, Chien KR. Cardiac hypertrophy induced by mitogen-activated protein kinase kinase 7, a specific activator for c-Jun NH2-terminal kinase in ventricular muscle cells. J Biol Chem. 1998;273(10): 5423-5426.
107. Nicol RL, Frey N, Pearson G, Cobb M, Richardson J, Olson EN. Activated MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophy. EMBO J. 2001;20(11): 2757-2767.
108. Marber MS, Rose B, Wang Y. The p38 mitogenactivated protein kinase pathway - a potential target for intervention in infarction, hypertrophy, and heart failure. J Mol Cell Cardiol. 2011;51(4): 485-490.
109. Nishida K, et al. p38alpha mitogen-activated protein kinase plays a critical role in cardiomyocyte survival but not in cardiac hypertrophic growth in response to pressure overload. Mol Cell Biol. 2004;24(24): 10611-10620.
110. Braz JC, et al. Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling. J Clin Invest. 2003;111(10): 1475-1486.
111. Liang Q, Bueno OF, Wilkins BJ, Kuan CY, Xia Y, Molkentin JD. c-Jun N-terminal kinases (JNK) antagonize cardiac growth through cross-talk with calcineurin-NFAT signaling. EMBO J. 2003; 22(19): 5079-5089.
112. Liu W, et al. Cardiac-specific deletion of mkk4 reveals its role in pathological hypertrophic remodeling but not in physiological cardiac growth. Circ Res. 2009;104(7): 905-914.
113. Liu W, et al. Deprivation of MKK7 in cardiomyocytes provokes heart failure in mice when exposed to pressure overload. J Mol Cell Cardiol. 2011; 50(4): 702-711.
114. Kyoi S, et al. Opposing effect of p38 MAP kinase and JNK inhibitors on the development of heart failure in the cardiomyopathic hamster. Cardiovasc Res. 2006;69(4): 888-898.
115. Westermann D, et al. Inhibition of p38 mitogenactivated protein kinase attenuates left ventricular dysfunction by mediating pro-inflammatory cardiac cytokine levels in a mouse model of diabetes mellitus. Diabetologia. 2006;49(10): 2507-2513.
116. Liu YH, et al. Inhibition of p38 mitogen-activated protein kinase protects the heart against cardiac remodeling in mice with heart failure resulting from myocardial infarction. J Card Fail. 2005; 11(1): 74-81.
117. Liu W, et al. Pak1 as a novel therapeutic target for antihypertrophic treatment in the heart. Circulation. 2011;124(24): 2702-2715.
118. Minamino T, et al. MEKK1 is essential for cardiac hypertrophy and dysfunction induced by Gq. Proc Natl Acad Sci U S A. 2002;99(6): 3866-3871.
119. Taglieri DM, et al. Ablation of p21-activated kinase-1 in mice promotes isoproterenol-induced cardiac hypertrophy in association with activation of Erk1/2 and inhibition of protein phosphatase 2A. J Mol Cell Cardiol. 2011;51(6): 988-996.
120. Taniike M, et al. Apoptosis signal-regulating kinase 1/p38 signaling pathway negatively regulates physiological hypertrophy. Circulation. 2008;117(4): 545-552.
121. Yamaguchi O, et al. Targeted deletion of apoptosis signal-regulating kinase 1 attenuates left ventricular remodeling. Proc Natl Acad Sci U S A. 2003; 100(26): 15883-15888.
122. Yamaguchi O, et al. Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis. J Clin Invest. 2004;114(7): 937-943.
123. Zhang D, et al. TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. Nat Med. 2000;6(5): 556-563.
124. Bush EW, McKinsey TA. Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors. Circ Res. 2010;106(2): 272-284.
125. Zhang CL, McKinsey TA, Chang S, Antos CL, Hill JA, Olson EN. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell. 2002;110(4): 479-488.
126. Nebbioso A, et al. Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes. EMBO Rep. 2009;10(7): 776-782.
127. Kim HJ, Bae SC. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res. 2011;3(2): 166-179.
128. Kee HJ, et al. Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation. 2006; 113(1): 51-59.
129. Kook H, et al. Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop. J Clin Invest. 2003;112(6): 863-871.
130. Kong Y, et al. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation. 2006;113(22): 2579-2588.
131. Gallo P, et al. Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure. Cardiovasc Res. 2008;80(3): 416-424.
132. Lee TM, Lin MS, Chang NC. Inhibition of histone deacetylase on ventricular remodeling in infarcted rats. Am J Physiol Heart Circ Physiol. 2007; 293(2):H968-H977.
133. Cardinale JP, et al. HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats. Hypertension. 2010;56(3): 437-444.
134. Iyer A, et al. Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats. Br J Pharmacol. 2010;159(7): 1408-1417.
135. Trivedi CM, et al. Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat Med. 2007;13(3): 324-331.
136. Montgomery RL, et al. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev. 2007;21(14): 1790-1802.
137. Shah MH, et al. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res. 2006; 12(13): 3997-4003.
138. Molife R, Fong P, Scurr M, Judson I, Kaye S, de Bono J. HDAC inhibitors and cardiac safety. Clin Cancer Res. 2007;13(3):1068.
139. Duvic M, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109(1): 31-39.
140. Olsen EA, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25(21): 3109-3115.
141. Elkayam U. Calcium channel blockers in heart failure. Cardiology. 1998;89(suppl 1): 38-46.
142. Goonasekera SA, et al. Decreased cardiac L-type Ca(2) channel activity induces hypertrophy and heart failure in mice. J Clin Invest. 2012;122(1): 280-290.
143. Marks AR. Calcium cycling proteins and heart failure: mechanisms and therapeutics. J Clin Invest. 2013;123(1): 46-52.
144. Nilius B, Owsianik G, Voets T, Peters JA. Transient receptor potential cation channels in disease. Physiol Rev. 2007;87(1): 165-217.
145. Eder P, Molkentin JD. TRPC channels as effectors of cardiac hypertrophy. Circ Res. 2011;108(2): 265-272.
146. Kuwahara K, et al. TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling. J Clin Invest. 2006;116(12): 3114-3126.
147. Nakayama H, Wilkin BJ, Bodi I, Molkentin JD. Calcineurin-dependent cardiomyopathy is activated by TRPC in the adult mouse heart. FASEB J. 2006;20(10): 1660-1670.
148. Wu X, Eder P, Chang B, Molkentin JD. TRPC channels are necessary mediators of pathologic cardiac hypertrophy. Proc Natl Acad Sci U S A. 2010; 107(15): 7000-7005.
149. Seth M, et al. TRPC1 channels are critical for hypertrophic signaling in the heart. Circ Res. 2009; 105(10): 1023-1030.
150. Kiyonaka S, et al. Selective and direct inhibition of TRPC3 channels underlies biological activities of a pyrazole compound. Proc Natl Acad Sci U S A. 2009;106(13): 5400-5405.
151. Moran MM, McAlexander MA, Biro T, Szallasi A. Transient receptor potential channels as therapeutic targets. Nat Rev Drug Discov. 2011;10(8): 601-620.
152. Molkentin JD, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998;93(2): 215-228.
153. Sussman MA, et al. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science. 1998;281(5383): 1690-1693.
154. Wilkins BJ, Molkentin JD. Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. Biochem Biophys Res Commun. 2004;322(4): 1178-1191.
155. Fiedler B, Wollert KC. Targeting calcineurin and associated pathways in cardiac hypertrophy and failure. Expert Opin Ther Targets. 2005;9(5): 963-973.
156. Shiojima I, Walsh K. Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway. Genes Dev. 2006;20(24): 3347-3365.
157. Smith CC, Yellon DM. Adipocytokines, cardiovascular pathophysiology and myocardial protection. Pharmacol Ther. 2011;129(2): 206-219.
158. McCullough PA, Philbin EF, Spertus JA, Kaatz S, Sandberg KR, Weaver WD. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol. 2002;39(1): 60-69.
159. Bleumink GS, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J. 2004;25(18): 1614-1619.